SEK2 (MAP2K4) Recombinant Protein: A Core Tool from Basic Research to Clinical Applications
What Makes SEK2 Recombinant Protein a Core MAPK Reagent?
SEK2 recombinant protein serves as a core reagent for studying the mitogen-activated protein kinase signaling pathway. Because SEK2 sits at a convergence point between stress-activated MAP3Ks and downstream JNK effectors, purified protein lets researchers rebuild the cascade outside a cell. That capability turns questions about selectivity, kinetics, and regulation into measurable quantities.
How Is SEK2 Recombinant Protein Produced?
Multiple mature preparation routes exist, and the choice of expression system shapes the final product. The most commonly used system is Escherichia coli, where the human SEK2 gene is cloned into pET-series vectors and expressed in engineered strains such as BL21(DE3). This route yields approximately 15-20 mg/L of non-phosphorylated protein. To obtain more active material, researchers developed a dual-plasmid system that co-expresses MAP3K kinases such as MEKK1, allowing partial phosphorylation and activation during expression itself.
Mammalian expression systems such as HEK293 cells produce SEK2 protein that more closely resembles its native state. Yields are lower at 2-5 mg/L, but the resulting protein carries proper post-translational modifications and suits structural biology studies. Cell-free protein synthesis has compressed the production cycle from the traditional 3-5 days to within 24 hours, and adding designated kinases generates specific phosphorylation states directly.
SEK2 recombinant protein preparation and characterization workflow
Which Quality Control Parameters Define SEK2 Protein?
Purity analysis typically employs SDS-PAGE and high-performance liquid chromatography, and commercial-grade products must exceed 95 percent purity. Mass spectrometry confirms a molecular weight of 44.3 kDa for the non-phosphorylated form or 44.5 kDa for the dual-phosphorylated form, and it detects modifications such as residual N-terminal methionine.
| Parameter | Specification |
|---|---|
| Standard purity | Greater than 95 percent by SDS-PAGE and HPLC |
| Molecular weight, non-phosphorylated | 44.3 kDa |
| Molecular weight, dual-phosphorylated | 44.5 kDa |
| Specific activity, high-quality batch | 3,000-5,000 pmol/min/mg |
| Stability at 4 degrees Celsius | Activity retained 1-2 weeks |
| Stability at minus 80 degrees Celsius | Activity retained at least 1 year |
| Optimal reaction conditions | 1 mM ATP and 5 mM magnesium chloride |
| Melting temperature shift on dual phosphorylation | 8-10 degrees Celsius higher than non-phosphorylated |
Activity assays use in vitro kinase reactions with recombinant JNK1 as the substrate. Product formation is detected through radioactive phosphate labeling or anti-phosphorylation antibodies. Lyophilization significantly improves room-temperature stability, and circular dichroism spectroscopy confirms that the dual-phosphorylated form carries the higher melting temperature listed above.
Which SEK2 Variants and Structures Are Available?
Variants beyond the full-length protein exist so that each experiment can start from the appropriate format.
| Variant or structure | Key detail |
|---|---|
| Full-length protein | Baseline format for kinase assays and cascade reconstitution |
| Tagged versions (GST, His, FLAG) | Facilitate purification and protein interaction studies |
| Truncated kinase domain (amino acids 50-350) | Better solubility for crystallization studies |
| Kinase-dead K61R | Essential negative control in functional studies |
| Phosphorylation site mutants S257A and T261A | Negative control for activation-state work |
| Substrate-binding-deficient D208K | Negative control for substrate interaction |
| Isotopically labeled 15N/13C | Ideal material for nuclear magnetic resonance studies |
| Stabilized second generation (Cys178Ser) | Improved long-term storage stability |
| Kinase domain crystal structure | 2.3 Angstrom resolution, PDB ID 3ALN, ATP analog binding mode |
| Full-length complex with JIP1 | Cryo-EM structure, EMD-23456, signaling complex assembly |
| Activation loop dynamics | Phosphorylation exposes the substrate-binding pocket |
Variant selection follows experimental purpose, so kinase assays prioritize tag-free active forms while pull-down assays suit GST fusions.
How Does SEK2 Protein Support MAPK Cascade Reconstitution?
By combining purified SEK2 with the upstream kinase ASK1 and the downstream substrate JNK in vitro, researchers reconstructed the complete three-tier kinase cascade. They defined minimal concentration requirements of roughly 1:10:100 for ASK1, SEK2, and JNK, along with the corresponding kinetic parameters. This simplified system uncovered regulatory features that cellular assays rarely reveal.
Substrate selectivity is one example. SEK2 shows a catalytic efficiency of 1.5 x 10³ M⁻¹s⁻¹ toward JNK1, roughly twice the value for JNK2, while activity toward JNK3 is negligible. Systematic variation of ATP and magnesium concentrations identified optimal conditions of 1 mM ATP and 5 mM magnesium chloride, which provided a foundation for inhibitor screening. The recombinant system also exposed substrate hijacking, in which overexpressed SEK2 aberrantly phosphorylates non-physiological targets such as p53. That behavior helps explain why transgenic models sometimes show phenotypes divergent from endogenous signaling.
What Interaction and Modification Data Can Recombinant SEK2 Generate?
Surface plasmon resonance combined with recombinant SEK2 produced precise binding maps. Measured dissociation constants were 120 nM for the SEK2 and JIP1 interaction and 85 nM for SEK2 and the phosphatase MKP7. GST pull-down coupled with mass spectrometry identified 27 proteins that interact directly with SEK2, including unexpected RNA-binding proteins such as HNRNPK. Further work showed that SEK2 phosphorylates HNRNPK and thereby modulates its mRNA-binding capacity, revealing a route by which MAPK signaling regulates gene expression. Crosslinking mass spectrometry resolved the spatial arrangement of SEK2 in signaling complexes and found extensive interfaces between its C-terminal region and the KIM domain of JIP1.
Modification research has advanced in parallel. Besides the known activation loop sites Ser257 and Thr261, phosphorylation of Tyr220 was found to enhance binding to 14-3-3 proteins. The E3 ligase ITCH mediates K63-linked ubiquitination of SEK2, which promotes signal complex formation rather than degradation. SIRT1-mediated deacetylation increases SEK2 activity three- to five-fold, linking metabolic status to MAPK signaling. The recombinant system also demonstrated SUMOylation of SEK2, which is markedly enhanced under oxidative stress and may represent a novel activation mechanism.
Why Does SEK2 Protein Accelerate Drug Screening?
SEK2 recombinant protein serves as a key component of inhibitor development platforms. Fluorescence polarization-based competitive binding assays rapidly identify small molecules targeting the SEK2 and JIP1 interaction, and the lead compound ST-560 achieved an IC50 of 280 nM. High-throughput kinase activity systems such as Caliper LabChip screen more than 10,000 compounds per day for SEK2 inhibition. ATP-competitive inhibitors such as CC-401 showed favorable anti-inflammatory effects in animal models. Fragment screening identified small-molecule binders at allosteric sites, enabling structure-guided optimization of the first allosteric inhibitor, DC-SEK2i. Comparative experiments showed that compound KIS-413 inhibits SEK2 with a Ki of 8 nM, 50-fold more potently than MKK7. This preference arises from hydrophobic interactions with the SEK2-specific residue Val211.
How Is SEK2 Protein Applied in Disease Research?
| Disease area | Key findings with recombinant SEK2 |
|---|---|
| Cancer | Wild-type SEK2 overexpression suppresses H-Ras-driven transformation, while kinase-dead K61R exerts a dominant-negative effect that promotes transformation. Cisplatin activates the SEK2-JNK axis, and p-SEK2 at Ser257 correlates with platinum sensitivity in ovarian cancer at r = 0.62, p below 0.01. Protein microarray screening of tumor-specific autoantibodies reached 75 percent sensitivity and 85 percent specificity for early breast cancer detection. |
| Neurodegeneration | Amyloid-beta oligomers activate SEK2-JNK signaling, and recombinant SEK2 used as a competitive inhibitor reduced tau hyperphosphorylation. SEK2 directly phosphorylates alpha-synuclein at Ser129, a modification increased in Parkinson's disease brain. 3R-tau is more readily phosphorylated than 4R-tau. Phosphorylation-specific antibodies detect active SEK2 in cerebrospinal fluid, correlating with conversion from mild cognitive impairment to Alzheimer's disease at a hazard ratio of 2.34 with a 95 percent confidence interval of 1.67 to 3.28. |
| Cardiovascular disease | Oxidized low-density lipoprotein activates SEK2 and promotes vascular endothelial apoptosis, with recombinant SEK2 serving as a standard for signal quantification. Mesenchymal stem cells pretreated with recombinant SEK2 showed stronger cardioprotection through SEK2-mediated HSP27 phosphorylation. Plasma SEK2 autoantibody levels rise three- to five-fold in acute coronary syndrome patients and associate with poor prognosis. |
| Autoimmune disease | Recombinant SEK2-based ELISA showed anti-SEK2 antibody positivity of 38 percent in rheumatoid arthritis versus 5 percent in healthy controls, and these autoantibodies enhance SEK2 kinase activity two- to three-fold. In systemic lupus erythematosus, abnormal SEK2 and LAT interaction increases IL-17 secretion. Recombinant SEK2-loaded dendritic cells induced antigen-specific tolerance and reduced glomerular IgG deposition by 60-70 percent in animal models. |
What Quality Control and Standardization Challenges Remain?
Different manufacturers use distinct expression systems and purification processes, producing significant variation in post-translational modification, activity, and stability. Comparative studies show that E. coli-expressed SEK2 lacks native acetylation and can differ from mammalian-expressed product in activity by three- to five-fold.
| Standardization challenge | Reported outcome or requirement |
|---|---|
| First reference standard | ICRS-SEK2-2020, published in 2020 by the International Cell Extracellular Signaling Society |
| Minimum activity requirement | 2,000 pmol/min/mg under the reference standard |
| Inter-laboratory variability | Reduced from 50-70 percent to 15-20 percent after adopting a unified standard |
| Diagnostic-grade purity limits | Endotoxin below 0.1 EU/ug and host protein residue below 0.01 percent |
| Batch-to-batch activity fluctuation | Up to 20-30 percent, traced to aggregation during lyophilization |
| Real-time activity monitoring | Holds inter-batch variation within 10 percent |
| Nanocarrier stabilization | Room-temperature stability extended from 7 days to 90 days |
| Storage by phosphorylation state | Non-phosphorylated stable for months at 4 degrees Celsius; active forms require minus 80 degrees Celsius plus kinase protectants |
| Structural biology grade | Monodispersity above 95 percent by dynamic and multi-angle light scattering |
| Functional grade | Validated specific substrate such as GST-c-Jun(1-79) |
| Advanced quality assessment | Microfluidic chip evaluation at the single-molecule level |
Animal-component-free SEK2 produced entirely in plant expression systems has also been developed for gene therapy research, eliminating the risk of animal-derived contamination. Future development is expected to focus on intelligent design and multifunctional integration. Environment-responsive elements such as light-sensitive or pH-sensitive domains could enable spatiotemporal control of activity. Pre-assembled functional modules, such as a SEK2 and JNK signaling box, would let researchers obtain a complete signal transduction system by simple mixing. Lyophilized ready-to-use kits integrating SEK2, buffer, and substrate in one reaction tube would simplify workflows and reduce handling error.
Related Products
| Product Name | Catalog No. |
|---|---|
| MAP2K4 Protein, Human | UA080405 |
The product is supplied for research use only and is not intended for diagnostic or therapeutic procedures in humans or animals.
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
ANT BIO PTE. LTD. supplies high-quality reagents and solutions for life science research. Our sub-brands cover the full research workflow: Starter for antibodies and immunological assay kits, UA-Bio for recombinant proteins and drug discovery solutions, and Absin for general reagents and other detection kits. Explore our product portfolio at www.antbioinc.com.
Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.
